Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data abstraction was performed by the participating physician.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Capmatinib | |||
| IO monotherapy | |||
| Chemotherapy alone | |||
| IO + chemotherapy |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Time-to-treatment discontinuation (TTD) | Up to approximately 5 years | |
| Real-world overall response rate (rwORR) | Proportion of patients with best overall response of either a complete response (CR) or partial response (PR) to the line of therapy based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or per healthcare professional (HCP) assessment. | Up to approximately 5 years |
| Real-world disease control rate (rwDCR) | Proportion of patients with best overall response of either a CR+PR or stable disease to the line of therapy based on RECIST version 1.1, or per HCP assessment. | Up to approximately 5 years |
| Real-world duration of response (rwDOR) | Time from the date of first documented CR or PR to the first documented systemic disease progression or death due to any cause. | Up to approximately 5 years |
| Real-world progression-free survival (rwPFS) | Time from start of therapy until the earliest of a clinically documented systemic disease progression. | Up to approximately 5 years |
| Overall survival (OS) | Time from start of therapy until death. | Up to approximately 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients per demographic category | Demographic categories included sex, race/ethnicity, and insurance status. | Baseline |
| Mean age | Baseline |
Not provided
Inclusion Criteria:
Patient was aged ≥ 18 years at the time of NSCLC diagnosis.
Had histologically confirmed advanced (stage IIIB, IIIC, or IV) NSCLC with MET exon 14 skipping mutation.
Initiated first-line (1L) treatment for aNSCLC between 1 January 2017 and date of data abstraction with one of the following treatment regimen:
Had ≥ 6 months of potential follow-up time after the initiation of 1L treatment for aNSCLC, except if the patient died sooner.
Living or deceased at the time of chart abstraction.
Exclusion Criteria:
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis | East Hanover | New Jersey | 07936 | United States |
Not provided
Not provided
Not provided
Not provided
| Number of patients per clinical characteristic category | Clinical characteristics included staging, presence and site(s) of metastases, number of lesions, and performance status. | Baseline |
| Number of patients per comorbidity | Up to 6 months pre-baseline |